Cancer-Associated Arrhythmia
Definition
Cardiac arrhythmias in patients with cancer or cancer survivors arising from the direct effects of anticancer therapy, secondary cardiotoxicity (heart failure, ischaemia, myocarditis), electrolyte abnormalities, or the cancer itself. Atrial fibrillation is the most common, but QT prolongation/ventricular arrhythmias and bradyarrhythmias also occur across all major drug classes.
Key Concepts
Epidemiology and the Cancer–AF Bidirectional Relationship
- The cancer–AF relationship is bidirectional: cancer patients have higher AF incidence, and AF patients have higher cancer incidence, likely from shared risk factors (advanced age, inflammation, metabolic disorders). (sources/arrhythmia-cardio-oncology-aha-2021, rating: very high)
- A study of >15,000 patients confirmed higher prevalent AF in cancer vs. non-cancer controls; AF also occurs in 2–16% of patients during active cancer therapy (post-lung surgery up to 32%). (sources/arrhythmia-cardio-oncology-aha-2021, sources/Cardio-Oncology-ESC-2022)
- Cancer-associated AF carries 2× higher stroke/thromboembolism risk and 6× higher HF risk versus AF in the non-cancer population. (sources/Cardio-Oncology-ESC-2022, rating: very high)
Drug-Specific AF Incidence
| Drug class | Agent | AF incidence | Key mechanism |
|---|---|---|---|
| Anthracyclines | Doxorubicin | 10.3%; up to 56.6% if LVD | Secondary to cardiomyopathy |
| Alkylating agent / HSCT | Melphalan | 11% (melphalan-based) | Direct + HSCT-related |
| BTK inhibitor | Ibrutinib | 3.5–16%; RR 4.69 (95% CI 2.17–7.64) | BTK/Tec/PI3K; Ca²⁺ dysregulation |
| BTK inhibitor (2nd gen) | Acalabrutinib | 4.1% | Higher BTK selectivity |
| BTK inhibitor (3rd gen) | Zanubrutinib | 2% | Higher BTK selectivity |
| ICI | Nivolumab/Pembrolizumab | 25–30% in myocarditis cohorts | ICI-driven myocarditis → AF |
| CAR-T therapy | Tisagenlecleucel/Axicabtagene | 7.5% | Cytokine release syndrome |
| BCR-ABL TKI (3rd gen) | Ponatinib | 1.9–7% | Unclear |
| VEGFi | Sorafenib + 5-FU | 5.1% (small series) | Unclear |
(sources/arrhythmia-cardio-oncology-aha-2021)
Ibrutinib and AF — Detailed Mechanism
- Meta-analysis of 8 RCTs (n=2,580): ibrutinib relative risk for AF 4.69 (95% CI 2.17–7.64, P<0.001). (sources/arrhythmia-cardio-oncology-aha-2021)
- Proposed mechanisms: on-target BTK inhibition; off-target Tec kinase inhibition; PI3K pathway inhibition; enhanced automaticity from altered sarcoplasmic reticulum calcium handling.
- Patients developing AF on ibrutinib have increased risk of mortality, likely from ischaemic or haemorrhagic cerebrovascular events.
- Newer-generation BTKi (acalabrutinib, zanubrutinib) have significantly lower AF rates due to higher BTK selectivity; choice between agents should factor in individual AF risk. (sources/arrhythmia-cardio-oncology-aha-2021)
AF Management in Cancer — Key Principles
- Follow general population algorithms with attention to drug-drug interactions (CYP 3A4, CYP 2D6, P-glycoprotein systems). (sources/arrhythmia-cardio-oncology-aha-2021, sources/cardio-oncology-drug-aha-2022)
- β-blockers: preferred rate control agent.
- Diltiazem/verapamil: use with caution — CYP 3A4 inhibition increases cancer drug concentrations.
- Digoxin: use with caution — ibrutinib and other P-glycoprotein inhibitors increase digoxin toxicity.
- Dronedarone: avoid in cancer — CYP 3A4 + P-glycoprotein effects cause dangerous drug accumulation.
- Amiodarone: commonly used but increases cancer drug concentrations via same metabolic pathways; monitor closely.
- Rhythm control: EAST-AFNET 4 benefit not established in cancer patients; cardioversion less durable in inflammatory cancer milieu; antiarrhythmic drug interactions with cancer therapy require careful pharmacological review. (sources/arrhythmia-cardio-oncology-aha-2021)
Anticoagulation in Cancer-Associated AF
- CHA₂DS₂-VASc is the recommended stroke risk scoring tool but may underestimate thromboembolic risk in cancer patients — cancer-specific predictors are not captured. (sources/arrhythmia-cardio-oncology-aha-2021)
- HAS-BLED underestimates bleeding risk in cancer — does not account for thrombocytopenia or intracranial metastases; cancer-specific bleeding risk algorithms are urgently needed. (sources/arrhythmia-cardio-oncology-aha-2021)
- DOACs preferred over warfarin for non-valvular AF in cancer patients: ARISTOTLE subgroup (n=1,236 cancer patients) confirmed apixaban superior to warfarin for stroke/systemic embolism; ENGAGE AF-TIMI 48 showed similar results for edoxaban. (sources/arrhythmia-cardio-oncology-aha-2021)
- DOAC drug interactions: All DOACs interact with P-glycoprotein (dabigatran most); rivaroxaban/apixaban also metabolised via CYP 3A4 — caution with ibrutinib (CYP 3A4 inducer).
- Aspirin: No longer recommended for AF stroke prevention; higher risk in cancer due to thrombocytopenia and ibrutinib platelet dysfunction. (sources/arrhythmia-cardio-oncology-aha-2021)
- TBIP algorithm (ESC 2022): Thrombotic risk + Bleeding risk + drug–drug Interactions + Patient preferences. See concepts/Cancer-Therapy-Related-CV-Toxicity. (sources/Cardio-Oncology-ESC-2022)
QT Prolongation in Cancer
Epidemiology and Mechanism
- QT prolongation incidence up to 22% across cancer drug classes; arsenic trioxide highest at 26–93% (acute promyelocytic leukaemia). (sources/arrhythmia-cardio-oncology-aha-2021)
- Mechanisms: direct K⁺ channel blockade; PI3K signalling pathway inhibition (many TKIs) → delayed ventricular repolarization.
- Life-threatening arrhythmias remain rare (<1%) despite high QT prolongation rates — cancer therapy interruption requires collaborative oncology/cardiology/patient decision. (sources/arrhythmia-cardio-oncology-aha-2021)
QT Measurement in Cancer Patients
- Manual calculation in lead II or V5 averaged over 3–5 beats (sinus arrhythmia) or 10 beats (during AF). (sources/arrhythmia-cardio-oncology-aha-2021)
- Fridericia formula (QTcF = QT/RR^(1/3)) preferred over Bazett in cancer population — more accurate at heart rate extremes. (sources/arrhythmia-cardio-oncology-aha-2021)
- JT interval (QT − QRS) can be used with bundle branch block or ventricular pacing, but is difficult to implement clinically.
Monitoring and Management
- No standardised QT monitoring protocol exists — follow drug-label instructions; novel therapeutics require ECG after first dose and after each dose change. Standardised protocols are urgently needed. (sources/arrhythmia-cardio-oncology-aha-2021)
- Arrhythmic risk threshold: QTc >500 ms or change from baseline >60 ms. (sources/arrhythmia-cardio-oncology-aha-2021)
- Treatment: Discontinue non-essential QT-prolonging drugs; correct electrolytes (K⁺, Mg²⁺); IV magnesium sulfate for TdP; maintain HR >100 bpm with isoproterenol or temporary pacing; ACLS/lidocaine for refractory cases. (sources/arrhythmia-cardio-oncology-aha-2021)
- Mexiletine: Emerging evidence for arsenic-induced QT prolongation and recurrent TdP prevention; further RCT evidence needed for broader cancer use. (sources/arrhythmia-cardio-oncology-aha-2021)
- See concepts/Torsades-de-Pointes for general TdP management.
Ventricular Arrhythmias
- Chemotherapy-induced sustained VT/VF is relatively rare; higher in advanced metastatic disease. (sources/arrhythmia-cardio-oncology-aha-2021)
- Ibrutinib: Associated with VA independent of QT prolongation (ibrutinib may actually shorten QT); enhanced automaticity and triggered activity are proposed mechanisms. (sources/arrhythmia-cardio-oncology-aha-2021)
- Anthracyclines: VA risk is secondary to anthracycline-induced LV systolic dysfunction + electrolyte abnormalities (hypokalemia) rather than direct proarrhythmic drug effect. (sources/arrhythmia-cardio-oncology-aha-2021)
- ICD criteria: Standard primary prevention guidelines apply — LVEF ≤35%, NYHA II–III, life expectancy >1 year (chemotherapy-induced cardiomyopathy is not excluded from ICD indication). (sources/arrhythmia-cardio-oncology-aha-2021)
- CRT in chemotherapy-induced cardiomyopathy — MADIT-CHIC trial: Single-arm, prospective multicentre study in patients with chemo-induced cardiomyopathy + LVEF ≤35% + LBBB (median QRS 152 ms) on optimal GDMT. CRT produced significant improvement in LVEF, LV volume reduction, LA volume reduction, and HF symptom improvement at 6 months. CRT-pacemaker (not only CRT-D) is appropriate even with life expectancy <1 year for symptom palliation. (sources/arrhythmia-cardio-oncology-aha-2021)
Bradyarrhythmias and Conduction Disease
| Drug | Bradycardia incidence | Notes |
|---|---|---|
| Paclitaxel | Up to 30% (asymptomatic sinus) | Reversible; advanced forms atypical |
| Thalidomide | Up to 40% sinus | Some require pacemaker |
| 5-Fluorouracil | ~12% symptomatic (one series) | Lower in systematic reviews |
| Ibrutinib | 2.3% conduction defects | 42% high-grade/complete AV block; 18% fatal |
| Crizotinib/ceritinib | Common but mild | Rare symptomatic episodes |
| ICI (nivolumab etc.) | 17% conduction disorders in cardiotoxicity cohort | First manifestation of myocarditis; 80% CV mortality |
(sources/arrhythmia-cardio-oncology-aha-2021)
- ICI-associated AV block: High-degree AV block may be the first sign of ICI-related myocarditis (1% overall, 50% mortality); in one series conduction disorders carried 80% vs 16% CV mortality. (sources/arrhythmia-cardio-oncology-aha-2021)
- Clinical pearl: Patients on AV nodal blocking drugs should have prophylactic dose reduction considered before starting bradycardic cancer agents (taxanes, ALK inhibitors, ibrutinib). (sources/arrhythmia-cardio-oncology-aha-2021)
- Pre-pacemaker assessment: AHA/ACC/HRS Class I: screen and treat sleep-disordered breathing before pacemaker implantation (SDB commonly causes nocturnal bradycardia reversible with CPAP). (sources/sdb-arrhythmia-aha-2022)
Contradictions / Open Questions
- Dedicated prospective studies evaluating true arrhythmia incidence in cancer are lacking — most evidence is retrospective; true incidence is likely underestimated. (sources/arrhythmia-cardio-oncology-aha-2021)
- Standard stroke and bleeding risk scores (CHA₂DS₂-VASc, HAS-BLED) are not validated in cancer populations; cancer-specific algorithms are urgently needed. (sources/arrhythmia-cardio-oncology-aha-2021)
- Whether early rhythm control (EAST-AFNET 4) provides the same benefit in cancer patients as in the general AF population is unknown — cancer patients were not enrolled. (sources/arrhythmia-cardio-oncology-aha-2021)
- Ibrutinib VA independent of QT shortening — the mechanism (enhanced automaticity vs triggered activity) has not been definitively characterised or used to identify high-risk patients. (sources/arrhythmia-cardio-oncology-aha-2021)
- Prophylactic antiarrhythmic therapy before HSCT has not been tested in RCTs despite correlational data linking pre-existing arrhythmias with post-HSCT mortality. (sources/arrhythmia-cardio-oncology-aha-2021)
Connections
- Related to concepts/Cardio-Oncology
- Related to concepts/Cancer-Therapy-Related-CV-Toxicity
- Related to concepts/Autonomic-Dysfunction-in-Cancer
- Related to concepts/Drug-Induced-Arrhythmia
- Related to concepts/Torsades-de-Pointes
- Related to entities/Atrial-Fibrillation
- Related to entities/Heart-Failure
- Related to sources/arrhythmia-cardio-oncology-aha-2021
- Related to sources/cardio-oncology-drug-aha-2022 — PK/PD drug interaction tables for antiarrhythmics with cancer drugs
- Related to sources/Cardio-Oncology-ESC-2022